Loading...
Market
Will Guardant Health's Shield blood test achieve over 20% adoption rate in the US healthcare market by end of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Healthcare market reports, adoption rate studies, or official Guardant Health press releases
Story
FDA Approves Guardant Health's Shield Blood Test for Colorectal Cancer Screening
Aug 7, 2024, 12:11 PM
The US FDA has approved Guardant Health's Shield blood test as the first blood test for primary screening of colorectal cancer (CRC) in adults aged 45 and above at average risk. This approval marks a significant advancement in non-invasive cancer screening options. Additionally, the utility of Guardant Reveal, another liquid biopsy test by Guardant Health, has been validated in the COSMOS study published in Clinical Cancer Research. The study confirms the test's effectiveness in predicting recurrence in colorectal cancer, particularly in Stage II and higher cases.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Below 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
Above 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Below $100 million • 25%
$100 million - $200 million • 25%
$200 million - $300 million • 25%
Above $300 million • 25%
Less than 100,000 • 25%
100,000 to 500,000 • 25%
500,000 to 1,000,000 • 25%
More than 1,000,000 • 25%
Guardant Health becomes the market leader • 25%
Guardant Health is among the top 3 • 25%
Guardant Health remains in the top 5 • 25%
Guardant Health does not make it to the top 5 • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%